Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemist...(e a number of complicated and time-inten...)

Date:7/29/2008

e a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to product performance, future products and future market opportunities. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen manufacturing problems; regulatory developments and practices regarding testing; customer and market acceptance of the product; our ability to develop and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the products; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and in i
'/>"/>

SOURCE Cepheid Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related biology technology :

1. Cepheid Reports Second Quarter Revenue of $42.1 Million
2. Cepheid to Webcast Analyst Event
3. Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast
4. Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
5. Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico
6. Cepheid Signs Group Purchasing Contract with Novation, the Nations Largest Healthcare Contracting Organization
7. Cepheid to Present at the Robert W. Baird Growth Stock Conference and the Bank of America Healthcare Conference
8. Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results
9. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
10. Cepheid Reports Fourth Quarter and Full Year 2007 Results
11. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market